Core Viewpoint - The investor relations management system of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. aims to enhance communication between the company and its investors, ensuring compliance with legal regulations and promoting transparency and trust [1][2][3]. Summary by Sections General Principles - The investor relations management is designed to facilitate the exercise of shareholder rights, information disclosure, interactive communication, and handling of investor requests [2]. - The basic principles include compliance, equality, proactivity, and honesty [2]. Objectives of Investor Relations Management - The objectives include improving communication with investors, establishing a stable investor base, enhancing corporate culture, increasing transparency in information disclosure, and maximizing overall and shareholder interests [3]. Communication Content - Key communication topics include the company's development strategy, legal information disclosures, operational management information, risks and challenges, corporate culture, and shareholder rights [3][4]. Communication Methods - Various communication methods are employed, including designated media for information disclosure, company website, performance briefings, one-on-one communications, and investor meetings [5][7]. Investor Meetings - The company is required to hold investor meetings under specific circumstances, such as when cash dividends do not meet regulations or when there are significant market events [8][12]. Responsibilities of the Board Secretary - The board secretary is responsible for managing investor relations, organizing communication activities, and ensuring timely responses to investor inquiries [10][11]. Training and Compliance - The company provides training for personnel involved in investor relations and ensures compliance with information disclosure regulations [12][13]. Prohibited Actions - Certain actions are prohibited during investor relations activities, including disclosing undisclosed significant information, providing misleading information, and unfair treatment of minority shareholders [13][14].

Core Viewpoint - The management system for subsidiaries of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. aims to enhance internal management, maintain the overall image of the listed company, and protect investor interests through structured governance and operational guidelines [1]. Group 1: General Provisions - The system is established based on relevant laws and regulations, including the Company Law of the People's Republic of China and the Shanghai Stock Exchange Listing Rules [1]. - Subsidiaries are defined as independent legal entities established according to the company's strategic planning and business development needs, which can be wholly-owned or controlled [1]. Group 2: Governance Structure Management - Subsidiaries must establish a sound corporate governance structure and operational systems in accordance with the Company Law and relevant regulations [2]. - The company exercises management, coordination, supervision, and assessment functions through participation in the subsidiaries' shareholder and board meetings [3]. Group 3: Personnel Management - The company appoints or recommends directors, supervisors, and senior management for subsidiaries, ensuring compliance with laws and company policies [4]. - The responsibilities of appointed personnel include ensuring adherence to laws and regulations, coordinating between the company and subsidiaries, and protecting the company's interests [5]. Group 4: Financial Management - Subsidiaries must adhere to the company's financial management requirements, ensuring the legality and completeness of accounting records and effectively controlling operational risks [6]. - Financial management tasks include compliance with national fiscal and tax policies, and the preparation of financial statements according to applicable accounting standards [6]. Group 5: Investment Management - Subsidiaries require company approval for technical reform projects and external investments, ensuring alignment with the company's development strategy [7]. - Investment projects must undergo feasibility studies and be reported to the company's management for decision-making [8]. Group 6: Information Management and Reporting - Subsidiaries are obligated to provide timely and accurate information that may significantly impact the company's image [9]. - Regular financial reports and updates on ongoing projects must be submitted to the company's board within specified timeframes [10]. Group 7: Internal Audit Supervision - The company conducts regular audits of subsidiaries to ensure compliance and assess economic efficiency [11]. - Subsidiaries must cooperate with audits and implement recommendations from approved audit reports [12].

杭州天目山药业股份有限公司总经理工作细则 杭州天目山药业股份有限公司 总经理工作细则 （2025 年 8 月修订） 第一章 总 则 第一条 为完善杭州天目山药业股份有限公司（以下简称"公 司"）的治理结构，明确总经理职权、权限，根据中华人民共和国公 司法（以下简称"《公司法》"）、《上海证券交易所股票上市规 则》和《上市公司自律监管指引第 1 号——规范运作》等法律、法规 以及《杭州天目山药业股份有限公司章程》（以下简称"公司章 程"）的规定，结合本公司实际，特制订本工作细则。 第二条 本细则适用人员范围为总经理经营班子成员，即总经理、 副总经理、董事会秘书、财务总监。 第三条 总经理主持公司日常经营和管理工作，组织实施董事会决 议，对董事会负责。公司经理人员履行职权，应符合相关法律法规、 规范性文件和《公司章程》的规定，并遵守本细则的规定。 第二章 总经理的任职资格与任免程序 第四条 公司设总经理一名，由董事长提名，并经董事会聘任或解 聘。总经理对董事会负责，履行《公司章程》规定的职权。 第五条 总经理任职应当具备下列条件： （一）有较丰富的管理知识和实践经验，具有较强的经营管理能 力； （二）有调动员工积 ...

杭州天目山药业股份有限公司高级管理人员责任追究管理办法 杭州天目山药业股份有限公司 高级管理人员责任追究管理办法 （2025 年 8 月修订） 第一章 总 则 第一条 为进一步促使公司总经理、副总经理、财务总监和董事会秘 书等高级管理人员及各子公司负责人全面、认真、合法履行岗位职责、加 强各级领导队伍建设，在严格管理、严肃追究中树立责任意识，减少和避 免因决策失误给国家、企业和股东造成重大损失或对职工合法权益造成严 重侵害，根据相关法规及《公司章程》制定本办法。 第二条 责任追究是高级管理人员、各子公司负责人在履行职责过程 中发生失职、渎职、失误或其他个人原因，对公司发展或工作造成不良影 响时，对高级管理人员、各子公司负责人的责任追究和处理。 第三条 本办法适用于公司高级管理人员、各子公司负责人。 第四条 责任追究坚持以下原则： 响； 重后果； 不良影响的特大安全事故和重大案件； 弄虚作假的； 第二章 职责划分 第五条 公司薪酬与考核委员会负责收集、汇总与追究责任有关的资 料，按制度规定提出相关方案，上报公司董事会。 | 第六条 公司审计部门负责公司高级管理人员、各子公司负责人的离 | | --- | | 任 ...

杭州天目山药业股份有限公司董事和高级管理人员持有并买卖本公司股票管理制度 杭州天目山药业股份有限公司 董事和高级管理人员持有并买卖本公司股票管理制度 （2025 年 8 月修订） 第一章 总 则 第一条 为加强杭州天目山药业股份有限公司（以下简称"公司"） 对董事和高级管理人员所持有及买卖本公司股份及变化的管理，根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票 上市规则》（以下简称"《股票上市规则》"）、《上市公司董事和高 级管理人员所持本公司股份及其变动管理规则》《上海证券交易所上市 公司自律监管指引第15号——股东及董事、高级管理人员减持股份》等 法律、行政法规、部门规章和《杭州天目山药业股份有限公司章程》（ 以下简称"《公司章程》"）等规定，制定本制度。 第二条 本制度适用于公司董事和高级管理人员所持本公司股份及 其变动的管理。公司董事和高级管理人员委托他人代行上述行为，视 作本人所为。 第三条 公司董事和高级管理人员所持本公司股份，是指登记在其 名下和利用他人账户持有的所有本公司股份。 公司董事和高级管理人员从事融资融 ...

杭州天目山药业股份有限公司关联交易管理制度 杭州天目山药业股份有限公司 （以下简称 《股票上市规则》） 、《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作》 《上海证券交易所上市公司自律监管指引第 5 号——交易与关 联交易》等相关法律、法规、规范性文件及《公司章程》的相关规定，制 定本制度。 第二条 公司进行关联交易，需保证关联交易的合法合规性、必要性 和公允性，保持公司的独立性，不得利用关联交易调节财务指标，损害公 司利益。交易各方不得隐瞒关联关系或者采取其他手段，规避公司的关联 交易审议程序和信息披露义务。公司关联交易应当遵循以下基本原则： （一）平等、自愿、等价、有偿原则； 关联交易管理制度 （2025 年 8 月修订） 第一章 总则 第一条 为规范杭州天目山药业股份有限公司（以下简称"公司"）的 关联交易行为，加强公司关联交易管理工作，保护投资者特别是中小投资 者的合法权益，提高公司治理水平，根据《中华人民共和国公司法》《上 市公司信息披露管理办法》《上市公司监管指引第 8 号——上市公司资金 往来、对外担保的监管要求》 《上海证券交易所股票上市规则》 （二）公平、公正、公开原则； （三 ...

Core Viewpoint - The compensation management system for directors and senior management at Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. aims to enhance the evaluation of work performance, establish an incentive and restraint mechanism, and align with modern corporate governance principles [1][2]. Group 1: General Principles - The compensation management system applies to directors elected by the shareholders and senior management appointed by the board [1]. - The principles of compensation management include a combination of labor distribution with responsibilities, linking income levels to company performance, considering long-term interests, and ensuring competitive compensation compared to market standards [2][3]. Group 2: Management Structure - The board of directors establishes a Compensation and Assessment Committee responsible for managing, assessing, and supervising the compensation of directors and senior management [3]. - The committee proposes compensation standards and performance assessment plans, which require approval from the board and shareholders before implementation [3][4]. Group 3: Compensation Composition and Standards - Compensation for directors includes allowances for independent and external directors, with specific standards set at 100,000 yuan/year for independent directors and 40,000 yuan/year for non-independent directors [4]. - Internal directors' compensation is based on a salary system, with the chairman's salary ranging from 500,000 to 3,000,000 yuan/year, subject to board approval [4][5]. - Senior management's compensation consists of a basic salary and performance rewards, with basic salaries ranging from 400,000 to 2,000,000 yuan/year for general managers and 300,000 to 1,500,000 yuan/year for other senior roles [5][6]. Group 4: Performance Assessment Principles - Independent directors do not participate in internal assessments linked to compensation, while internal directors and senior management are assessed based on annual performance [6]. - The annual performance rewards are determined by the Compensation and Assessment Committee and require board approval for execution [6]. Group 5: Compensation Management and Adjustments - The compensation system should adapt to the company's development strategy and operational changes, with adjustments proposed by the Compensation and Assessment Committee [7][8]. - Adjustments are based on industry salary levels, inflation, company profitability, organizational changes, and individual performance [7][8].

Core Points - The document outlines the investment management measures of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd to standardize external investment management, enhance compliance efficiency, and reduce investment risks [1][2] - The investment is defined as the company's allocation of funds, equity, land use rights, or other assessed assets for future returns [1] - Investments are categorized into short-term and long-term based on their duration, with specific definitions provided for each type [1][3] Investment Approval Process - The investment approval must adhere to the Company Law, Shanghai Stock Exchange rules, and the company's articles of association [3][4] - The company implements a professional management and hierarchical approval system for external investments [2][3] Decision-Making Bodies - The shareholders' meeting and the board of directors serve as the decision-making bodies for external investments [3][6] - Certain investment transactions require board approval and must be submitted to the shareholders' meeting if they meet specified thresholds [5][6] Investment Principles - Investments must comply with national laws, align with national industrial policies and the company's development strategy, and not adversely affect the company's main business [4][5] Short-term Investment Procedures - The financial management center provides a cash flow statement and identifies suitable short-term investment opportunities [9][10] - A strict joint control system is required for securities investments, ensuring that at least two personnel are involved in operations [9][10] Long-term Investment Management - Long-term investments are managed by the board office, with other departments participating in the preparation of investment plans [11][12] - Contracts for long-term investments must be reviewed by the company's legal counsel before signing [11][12] Investment Transfer and Recovery - The company can recover investments under specific circumstances, such as project completion or inability to repay debts [26][27] - Investment transfers must comply with the Company Law and the company's articles of association [28][29] Financial Management and Auditing - The financial management center is responsible for comprehensive financial records of investment activities and must conduct annual checks on investments [34][35] - Subsidiaries must report financial statements monthly to ensure compliance with the company's financial policies [38][39] Information Disclosure - The company must fulfill its information disclosure obligations according to relevant laws and regulations [41][42] - Subsidiaries are required to provide accurate and timely information to the company for external disclosure [43][44]

杭州天目山药业股份有限公司重大信息内部报告制度 杭州天目山药业股份有限公司 重大信息内部报告制度 杭州天目山药业股份有限公司重大信息内部报告制度 （2025 年 8 月修订） 第一章 总 则 第一条 为规范杭州天目山药业股份有限公司(以下简称"本公司"或 "公司")的重大信息内部报告工作，保证公司内部重大信息的快速传 递、归集和有效管理，及时、准确、全面、完整地披露信息，维护投资者 的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司信息披露管理办法》《上海证券交易所股票上市规则》(以下简 称"《股票上市规则》"）、《杭州天目山药业股份有限公司章程》（以 下简称"《公司章程》"）、《公司信息披露事务管理制度》等有关规 定，结合本公司实际，制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可 能对公司股票及其衍生品种交易价格产生较大影响的情形或事件时，按照 本制度规定负有报告义务的有关人员和公司，应当在第一时间将相关信息 向董事长和董事会秘书报告并告知董事会办公室的制度。 第三条 本制度所称"内部信息报告义务人"系指按照本制度规定负 有报告义务的有关人员或公司，包括 ...

杭州天目山药业股份有限公司内幕知情人管理制度 杭州天目山药业股份有限公司 内幕信息知情人登记管理制度 （2025 年 8 月修订） 第一章 总 则 第一条 为规范杭州天目山药业股份有限公司（以下简称"公司" 内幕信息管理行为，加强内幕信息保密工作，维护公司信息披露的公 开、公平、公正原则，根据《中华人民共和国公司法》《中华人民共 和国证券法》 （以下简称" 《证券法》 "）、 《上市公司信息披露管理办法》 《上市公司监管指引第 5 号——上市公司内幕信息知情人登记管理 制度》 《上海证券交易所股票上市规则》等有关法律、法规和《杭州 天目山药业股份有限公司章程》 （以下简称" 《公司章程》 "）、 《杭州天 目山药业股份有限公司信息披露事务管理制度》的相关规定，制定本 制度。 第二条 公司董事会是内幕信息的管理机构，董事会授权董事会 秘书为公司内幕信息管理工作负责人，董事会办公室具体负责公司内 幕信息的日常管理工作。 第三条 本制度规定的内幕信息知情人应做好内幕信息的保密工 作，未经董事会批准同意，公司任何部门和个人不得向外界泄露、报 道、传送有关公司内幕信息及信息披露的内容。 公司董事、高级管理人员及内幕信息 ...